Payment overview · 2025
General Payments
$6,531.24
3 reported records · 1 companies
Healthcare provider profile · identity verified
William Keith Debell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · TUSCALOOSA, AL · NPI 1184791329
Verified facts
What the public records show
CMS Open Payments records show William Keith Debell, M.D. received $6,531.24 in general payments during 2025 across 3 reported records.
Dexcom, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $6,531.24 | 100.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $6,128.00 | 1 |
| Travel and Lodging | $403.24 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $6,531.24 | 3 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $6,531.24 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 494 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 72 |
| Losartan Potassium | Losartan Potassium | 221 | 70 |
| Omeprazole | Omeprazole | 218 | 59 |
| Glimepiride | Glimepiride | 207 | 55 |
| Lisinopril | Lisinopril | 193 | 60 |
| Ozempic | Semaglutide | 183 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 161 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 52 |
| Jardiance | Empagliflozin | 146 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 46 |
| Meloxicam | Meloxicam | 138 | 46 |
| Metformin Hcl | Metformin Hcl | 131 | 37 |
| Mounjaro | Tirzepatide | 118 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 117 | 35 |
| Temazepam | Temazepam | 112 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 31 |
| Furosemide | Furosemide | 104 | 36 |
| Potassium Chloride | Potassium Chloride | 104 | 28 |
| Metformin Hcl Er | Metformin Hcl | 101 | 34 |
| Simvastatin | Simvastatin | 100 | 28 |
| Gabapentin | Gabapentin | 97 | 31 |
| Sertraline Hcl | Sertraline Hcl | 94 | 31 |
| Ezetimibe | Ezetimibe | 88 | 25 |
| Carvedilol | Carvedilol | 79 | 22 |
| Eliquis | Apixaban | 77 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 18 |
| Januvia | Sitagliptin Phosphate | 76 | 13 |
| Montelukast Sodium | Montelukast Sodium | 75 | 22 |
| Atenolol | Atenolol | 74 | 18 |
| Humalog | Insulin Lispro | 74 | 19 |
| Novolog Flexpen | Insulin Aspart | 72 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 67 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 19 |
| Famotidine | Famotidine | 64 | 22 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 14 |
| Chlorthalidone | Chlorthalidone | 60 | 20 |
| Synthroid | Levothyroxine Sodium | 59 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 13 |
| Novolog | Insulin Aspart | 56 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 18 |
| Allopurinol | Allopurinol | 49 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Prednisone | Prednisone | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 12 |
| Irbesartan | Irbesartan | 34 | 11 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 12 |
| Tramadol Hcl | Tramadol Hcl | 29 | 11 |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Baclofen | Baclofen | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Insulin Aspart | Insulin Aspart | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,531.24 · 3 records | Dexcom, Inc. | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error